TABLE 2.

Comparison of epidemiological characteristics, clinical features, treatment, and prognosis of NSCLC patients with ALK/ALK + EGFR/ALK + TP53 mutations.

		ALK	ALK + EGFR	ALK + TP53
Incidence		3%–13% a [9, 10]	0.3–1.3% b [9, 11]	23.4%–60% b [12, 13]
Age		Younger patients	Younger patients	Younger patients
Sex		No gender preference	Female	No gender preference
Ethnicity		Asian	Asian	Asian
Smoking		Never	Never	Are or have been
Pathology		LADC	LADC	LADC
Stage		advanced stage	advanced stage	advanced stage
Response to chemotherapy c		similar with ALK—	similar with ALK+	poorer than ALK+
Response to ALK‐TKIs d	ORR	81.6% [14], 73.9% [15], 65% [16], 60%–75.5% [17, 18, 19], 76.9% [20]	40% [15], 66.7% [16]	40% [14], 37.5% [20]
	DCR	95.9% [14]	—	73.3% [14]
mPFS	Chemotherapy	6.2m [13, 21] 7m [22], 8.1m [23],	—	2.6m [13, 21]
	ALK‐TKIs	29.9m [21], 6.9m [15], 11.7m [24], 12.5‐13 m [16, 25], 9.3‐11 m [17, 18, 19], 27.9m [26], 10.4–28.5 [27] 8.8 [28] 10.8 [29]	1.9m [15], 11.1m [16] 2m [30]	5.5m [21], 4.2m [24], 8m [25], 3.3m [20], 9.2m [26] 3.7 [28] 7.2 [29]
	EGFR‐TKIs	—	11.2m [9, 15], 10.3m [16]	—
mOS		50m [13], 23.7m [15], 34.2m [20],	18.5m [15]	15m [13], 21.4m [20]

Abbreviations: DCR, disease control rate; LADC, lung adenocarcinoma; m, month; mOS, median overall survival; mPFS, median progression‐free survival; ORR, objective response rate.

^a In all nonsmall cell lung cancer patients.

^b In ALK fusion mutation nonsmall cell lung cancer patients.

^c Platinum‐based first‐line chemotherapy regimen.

^d ALK‐TKI represented by crizotinib.